IP Library Granted Patent US 12,161,645
Granted Patent B2
US 12,161,645 · App. 18/606,903 · Granted Dec 10, 2024

Aryl-or heteroaryl-substituted benzene compounds

Inventors: Kevin W. Kuntz (Woburn, MA); Richard Chesworth (Concord, MA); Kenneth W. Duncan (Westwood, MA); Heike Keilhack (Belmont, MA); Natalie Warholic (Cambridge, MA); Christine Klaus (Waban, MA); Sarah K. Knutson (Lincoln, MA); Timothy J. N. Wigle (Waltham, MA); Masashi Seki (Tsukuba, JP); Syuji Shirotori (Tsukuba, JP); Satoshi Kawano (Tsukuba, JP)
Assignee: Epizyme, Inc.
A61K31/5377A61K31/4412A61K31/443A61K31/4433A61K31/4436A61K31/4439A61K31/444A61K31/4545A61K31/4709A61K31/496A61K31/506A61K31/551A61K31/553C07D213/64C07D401/12C07D405/12C07D405/14C07D409/12C07D413/12C07D417/12C07D491/08C07D491/107C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,161,645
App. No.
18/606,903
Granted
Dec 10, 2024
Kind
B2
Abstract

The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims (11)

1. A method of treating follicular lymphoma comprising administering to a human subject in need thereof a compound of the following formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is:

3. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of:

4. The method of claim 1 , wherein the compound is administered orally to the human subject in need thereof.

5. The method of claim 4 , wherein the compound is administered twice daily.

6. The method of claim 5 , wherein the compound is administered in an amount of from about 0.1 mg/day to about 3 g/day.

7. The method of claim 3 , wherein the pharmaceutically acceptable salt is a hydrobromic acid salt.

8. The method of claim 7 , wherein the compound is administered orally to the human subject in need thereof.

9. The method of claim 8 , wherein the compound is administered twice daily.

10. The method of claim 9 , wherein the compound is administered in an amount of from about 0.1 mg/day to about 3 g/day.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: KUNTZ, KEVIN W.; CHESWORTH, RICHARD; DUNCAN, KENNETH W.; KEILHACK, HEIKE; WARHOLIC, NATALIE; KLAUS, CHRISTINE; KNUTSON, SARAH K.; WIGLE, TIMOTHY J.N.
To: EPIZYME, INC.
Reel/Frame 068013/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: SEKI, MASASHI; SHIROTORI, SYUJI; KAWANO, SATOSHI
To: EISAI CO., LTD.
Reel/Frame 068013/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 068013/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: EISAI R&D MANAGEMENT CO., LTD.
To: EPIZYME, INC.
Reel/Frame 068013/0940 →